Pathogenesis of chronic immune thrombocytopenic purpura

Current Opinion in Hematology

Volumn 14, Issue 5, 2007, Pages 511-514

  Cines, Douglas B ^a   McMillan, Robert ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autoantibody; Immune thrombocytopenic purpura; Platelets; T lymphocytes

Indexed keywords

AUTOANTIBODY; FC RECEPTOR; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB IX; LYMPHOCYTE ANTIGEN; THROMBOCYTE ANTIBODY; THROMBOPOIETIN; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CELL CLONING; CELL FUNCTION; CELL MATURATION; CELL SPECIFICITY; CYTOTOXIC LYMPHOCYTE; DISEASE SEVERITY; GENETIC POLYMORPHISM; HISTORY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYSIS; MEGAKARYOCYTE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTOPOIESIS; TURNOVER TIME;

ANTIBODY FORMATION; AUTOANTIBODIES; B-LYMPHOCYTES; BLOOD PLATELETS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHRONIC DISEASE; HUMANS; IMMUNITY, CELLULAR; MEGAKARYOCYTES; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 34648826759     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282ba5552     Document Type: Review

References (38)

1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3-40.
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995-1008.
3. George JN, El-Harake MA, Aster RH. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams hematology. New York: McGraw-Hill; 1995. pp. 1315-1355.
4. Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Ann Rev Med 2005; 56:425-442.
5. Piessens WF, Wybran J, Manaster J, Strijckmans PA. Lymphocyte transformation induced by autologous platelets in a case of thrombocytopenic purpura. Blood 1970; 36:421-427.
6. Morimoto C, Abe T, Hara M, Homma M. Cell-mediated immune response in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 1977; 8:181-189.
7. Trent RJ, Clancy RL, Danis V, Basten A. Disordered immune homeostasis in chronic idiopathic thrombocytopenic purpura. Clin Exp Immunol 1981; 45:9-17.
8. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991; 78:2619-2625.
9. Kuwana K, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: role in production of antiplatelet autoantibody. J Clin Invest 1998; 102:1393-1402.
10. Kuwana M, Okazaki Y, Kaburaki J, et al. Spleen is the primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2003; 168:3675-3682.
11. McMillan R, Yelenosky RJ, Longmire RL. Antiplatelet antibody production by the spleen and bone marrow in immune thrombocytopenic purpura. In: Battisto JR, Streinlein JW, editors. Immunoaspects of the spleen. Amsterdam: North Holland Biomedical Press; 1976.
12. McMillan R, Lopez-Dee J, Bowditch R. Clonal restriction of platelet-associated anti-GPIIb/IIIa autoantibodies in patients with chronic ITP. Thromb Haemostas 2001; 85:821-823.
13. Roark JH, Bussel JB, Cines DB, Siegel DL. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 2002; 100:1388-1398. The findings suggest that antiplatelet antibodies in ITP derive from a restricted usage of specific heavy and light chain genes. If confirmed, identification of the pathogenic clones could lead to new approaches to selective immunosuppression in an antibody-specific manner.
14. Solanilla A, Pasquet JM, Viallard JF, et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005; 105:215-218.
15. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87:4245-4254.
16. Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Trans Med Rev 2003; 17:69-80.
17. Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004; 103:2645-2647.
18. Sukati H, Watson HG, Urbaniak SJ, Barker RN. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. Blood 2007; 109:4528-4538.
19. Harrington WJ, Sprague CC, Minnich V, et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38:433-469.
20. Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura: physiologic, serologic, and isotopic studies. Ann N Y Acad Sci 1965; 124:499-542.
21. McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol 2003; 25 (Suppl 1):57-61.
22. McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemostas 2003; 1:485-491.
23. Fabris F, Scandellari R, Ruzzon E, et al. Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 2004; 103:4562-4564. The authors find that the detection of platelet-specific antibodies is a useful prognostic marker in patients who meet the American Society of Hematology guidelines for ITP based upon clinical criteria. If confirmed, this article raises questions about the pathophysiology of thrombocytopenia in the antibodynegative population and potential changes in antibody titer and repertoire over time.
24. Berchtold P, Muller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 1997; 96:477-483.
25. Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with anti-Fcγ-receptor antibody. N Engl J Med 1986; 314:1236-1239.
26. Carcao MD, Blanchette VS, Wakefield CD, et al. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol 2003; 120:135-141.
27. Fujimoto TT, Inoue M, Shimomura T, Fujimura K. Involvement of Fc gamma receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. Br J Haematol 2007; 115:125-130.
28. Deckmyn H, De Reys S. Functional effects of human antiplatelet antibodies. Semin Thromb Hemost 1995; 21:46-59.
29. Heyns AP, Lotter MG, Badenhorst PN, et al. Kinetics and sites of destruction of 111-indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: a quantitative study. Am J Hematol 1982; 12:167-177.
30. Stoll D, Cines DB, Aster RH, Murphy S. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood 1985; 65:584-588.
31. Heyns AP, Badenhorst PN, Lotter MG, et al. Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111-In-labeled and homologous 51-Cr-labeled platelets differ. Blood 1986; 67:86-92.
32. Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence for both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33-40.
33. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93:704-706.
34. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult chronic ITP patients. Blood 2004; 103:1364-1369. This article shows that IgG antibodies in the plasma of patients with ITP suppress the development of normal megakaryocytes in vitro. This helps to explain the reduction in platelet production seen in some patients with ITP and the rationale for the proposed use of thrombopoietin receptor mimetics.
35. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102:887-895.
36. Houwerzijl EJ, Blom NR, van der Want JJL, et al. Ultrastructural study shows morphological features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103:500-506.
37. Olsson B, Andersson P, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9:1123-1124. The authors show that T lymphocytes from some patients with ITP lyse human platelets. This phenomenon may contribute to the failure of some patients to respond to splenectomy and may play a role in impaired platelet production as well.
38. Olsson B, Andersson PO, Jacobsson S, et al. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemostas 2005; 93:139-144.